{
    "clinical_study": {
        "@rank": "129497", 
        "arm_group": [
            {
                "arm_group_label": "QBM076 Part 1 Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "QBM076 will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "Placebo Part 1 Cohort 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "QBM076 Part 1 Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "QBM076 will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "Placebo Part 1 Cohort 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "QBM076 Part 1 Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "QBM076 will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "Placebo Part 1 Cohort 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "QBM076 Part 1 Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "QBM076 will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "Placebo Part 1 Cohort 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be provided to participants during 14 days in Part 1"
            }, 
            {
                "arm_group_label": "QBM076 Part 2", 
                "arm_group_type": "Experimental", 
                "description": "QBM076 will be provided to participants during 56 days in Part 2"
            }, 
            {
                "arm_group_label": "Placebo Part 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be provided to participants during 56 days in Part 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2 Part study. Part 1 is a safety and tolerability study in GOLD I-III COPD\n      patients. Part 2 is an efficacy study in GOLD I-III COPD patients."
        }, 
        "brief_title": "A Safety, Tolerability and Efficacy Study in COPD Patients With QBM076.", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "Part 1 is a double-blind, randomized, placebo-controlled, non-confirmatory study in chronic\n      bronchitis COPD patients. 32 patients will be enrolled in up to 4 cohorts. Patients will be\n      randomized in a 3:1 ratio. Part 1 will consist of up to 27-days of screening period, one\n      baseline period of 1 day, 13 days of bid dosing with study treatment, morning only treatment\n      on day 14, follow up visits on days 15 - 17, followed by a study completion evaluation.\n\n      Part 2 is a double-blind, randomized, placebo-controlled, non-confirmatory study in Gold\n      I-III chronic bronchitis COPD patients. 90 patients will be randomized in a 2:1 ratio. The\n      study will consist of up to 18 days of screening period, a 9 day run in period, one baseline\n      period of 1 day, 55 days of bid dosing, morning only dosing on day 56, a follow up visit on\n      day 57, followed by study completion evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part 1: Patients, smokers or ex-smokers with stable chronic bronchitis GOLD class I-III\n        chronic obstructive pulmonary disease (COPD); forced expiratory volume in 1 second \u226540% of\n        predicted and forced expiratory volume in 1 second:forced vital capacity ratio \u22640.7 post\n        bronchodilator, respectively; diffusing capacity of the lung for carbon monoxide \u226540%; a\n        stable medical regimen for at least 4 weeks prior to screening. Current smokers can be\n        enrolled if they currently smoke \u22641ppd for last 3 months.\n\n        Part 2: Patients, smokers or ex-smokers with stable chronic bronchitis GOLD class I-III\n        COPD; a stable medical regimen for at least 4 weeks prior to screening; high sensitivity C\n        reactive protein\u22651.5 mg/L; forced expiratory volume in 1 second \u226540% of predicted and\n        forced expiratory volume in 1 second:forced vital capacity ratio \u22640.7 post bronchodilator,\n        respectively; with mean lung clearance index 2.5% \u22658; Ex-smokers with at least 10 pack\n        year smoking history; or current smokers with at least 10 pack year smoking history who\n        smoke \u2264 1ppd on average for last 3 months.; evidence of air trapping \u2265 20% (based on\n        radiologic criteria)\n\n        Exclusion Criteria:\n\n        Part 1:Gold Class IV COPD, of moderate to significant emphysema, or evidence of\n        malignancy; medication considered potential for drug drug interaction; creatinine\n        clearance <30ml/min; more than 1 exacerbation requiring antibiotics or oral steroids\n        and/or hospitalization within 3 months of screening; women of child bearing potential Part\n        2: Gold Class IV COPD; medication considered a potential for drug drug interaction; serum\n        creatinine \u22651.9 mg/dL; more than 1 exacerbation requiring antibiotics or oral steroids\n        within 2 months and/or hospitalization within 3 months of screening; any malignancy;\n        evidence of severe emphysema as determined by HRCT; use of oral steroids, theophylline,\n        phosphodiesterase-4 inhibitors or oral antibiotic use (eg.macrolides); women of child\n        bearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "122", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972776", 
            "org_study_id": "CQBM076X2203", 
            "secondary_id": "2012-005615-92"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "QBM076 Part 1 Cohort 1", 
                    "QBM076 Part 1 Cohort 2", 
                    "QBM076 Part 1 Cohort 3", 
                    "QBM076 Part 1 Cohort 4", 
                    "QBM076 Part 2"
                ], 
                "description": "QBM076 taken orally twice per day during 14 days for Part 1 -  QBM076 taken orally twice per day during 56 days for Part 2", 
                "intervention_name": "QBM076", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo Part 1 Cohort 1", 
                    "Placebo Part 1 Cohort 2", 
                    "Placebo Part 1 Cohort 3", 
                    "Placebo Part 1 Cohort 4", 
                    "Placebo Part 2"
                ], 
                "description": "Placebo taken orally twice per day during 14 days for Part 1\nPlacebo taken orally twice per day during 56 days for Part 2", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "COPD, inflammation, small airways, LCI, PFTs, lung heterogeneity", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22903"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23225"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60596"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "Sector 5"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9QZ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "zip": "S10 2JF"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Romania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "10", 
        "official_title": "A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events will be counted within each treatment for each part of the study and corresponding percentages will be tabulated.", 
                "measure": "Occurrence of an adverse event in multiple doses of QBM076 for 14 days of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "LCI as measured by multiple breath nitrogen washout is the time taken to wash out nitrogen whilst breathing 100% oxygen. LCI will be measured at baseline and day 14. LCI will be analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction.", 
                "measure": "Change in Lung clearance Index (LCI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (day -1) and 56 days"
            }, 
            {
                "description": "Log sputum neutrophils will be analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction.", 
                "measure": "Change in absolute number of sputum neutrophils", 
                "safety_issue": "No", 
                "time_frame": "Baseline (day -1) and day 56"
            }, 
            {
                "description": "Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. Mixed model uses baseline TDI, baseline inhaled corticosteroid (ICS) use, FEV1 prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates.", 
                "measure": "Questionnaire TDI", 
                "safety_issue": "No", 
                "time_frame": "Baseline (day -1) and 56 days"
            }, 
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 will indicate improvement in lung function.", 
                "measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (day -1) and 56 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972776"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). AUC0-t will be listed by treatment and subject. Descriptive summary statistics will include mean (arithmetic and geometric), SD, and CV (arithmetic and geometric), median, minimum and maximum.", 
                "measure": "AUC0-t Plasma concentration of QBM076 between 0h and 72h on Days 1 and 14", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). Cmax will be listed by treatment and subject. Descriptive summary statistics will include mean (arithmetic and geometric), SD, and CV (arithmetic and geometric), median, minimum and maximum.", 
                "measure": "Cmax Plasma concentration of QBM076 between 0h and 72h on Days 1 and 14", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). Tmax will be listed by treatment and subject. Tmax is generally evaluated by a nonparametric method, median values and ranges will be given for this parameter", 
                "measure": "Tmax Plasma concentration of QBM076 between 0h and 72h on Days 1 and 14", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations will follow the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.", 
                "measure": "Change From Baseline in FEF25-75, FEV3/FVC, 1-(FEV3/FVC), FEV6, FEV1/FEV6 and post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "The change in CD11b expression will be presented as a percentage change from baseline on days 1 and 14", 
                "measure": "Change in CD11b expression from baseline", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). AUC0-t will be listed by treatment and subject. Descriptive summary statistics will include mean (arithmetic and geometric), SD, and CV (arithmetic and geometric), median, minimum and maximum.", 
                "measure": "AUC0-t Plasma concentration of QBM076 between 0h and 24h on Days 1 and 56", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). Cmax will be listed by treatment and subject. Descriptive summary statistics will include mean (arithmetic and geometric), SD, and CV (arithmetic and geometric), median, minimum and maximum.", 
                "measure": "Cmax Plasma concentration of QBM076 between 0h and 24h on Days 1 and 56", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "Blood samples will be taken from each subject participating in the study (placebo group and active treatment group). Tmax will be listed by treatment and subject. Tmax is generally evaluated by a nonparametric method, median values and ranges will be given for this parameter", 
                "measure": "Tmax Plasma concentration of QBM076 between 0h and 24h on Days 1 and 56", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "Log sputum neutrophils will be analyzed using a Bayesian model for repeated measurements. The model may investigate effects for pre-dose baseline, treatment, time, age, COPD class, treatment by time interaction, and baseline by time interaction.", 
                "measure": "Change in percentage sputum neutrophils", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "DLco involves measuring the partial pressure difference between inspired and expired carbon monoxide. Descriptive statistics will be provided by treatment for measurements performed at baseline, days 14, 28 and 56.", 
                "measure": "Change in diffusing capacity of the lung for carbon monoxide (DLco)", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "Multiple breath nitrogen washout involves administration of 100% oxygen, and measures the time taken to washout nitrogen. Parameters Scond and Sacin are measures taken from the curve of nitrogen concentration whilst being washed out from the lung during oxygen administration. Descriptive statistics will be provided by treatment at baseline and on days 14, 28, and 56.", 
                "measure": "Change in Scond/Sacin as measured by multiple breath nitrogen washout (MBNW)", 
                "safety_issue": "No", 
                "time_frame": "56 days"
            }, 
            {
                "description": "The change in CXCR2 receptor occupancy will be presented as a percentage change from baseline on days 1 and 14", 
                "measure": "Change in CXCR2 receptor occupancy from baseline", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}